CoChat
Sign Up
Cited by 210Gut microbiota and healthDementia and Cognitive Impairment ResearchTryptophan and brain disorders

The DOI matches its Crossref record; 369 of the 369 references it cites were found in a registry or an index.

Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia

Open access
Connell, Emily, Le Gall, Gwenaelle, Pontifex, Matthew G., Sami, Saber, Cryan, John F., Clarke, Gerard, Müller, Michael, Vauzour, David·2022·Molecular Neurodegeneration
DOI 10.1186/s13024-022-00548-6PMC PMC9204954
Open this paper in CoChat — free accountOpen PDF

Abstract

A consequence of our progressively ageing global population is the increasing prevalence of worldwide age-related cognitive decline and dementia. In the absence of effective therapeutic interventions, identifying risk factors associated with cognitive decline becomes increasingly vital. Novel perspectives suggest that a dynamic bidirectional communication system between the gut, its microbiome, and the central nervous system, commonly referred to as the microbiota-gut-brain axis, may be a contributing factor for cognitive health and disease. However, the exact mechanisms remain undefined. Microbial-derived metabolites produced in the gut can cross the intestinal epithelial barrier, enter systemic circulation and trigger physiological responses both directly and indirectly affecting the central nervous system and its functions. Dysregulation of this system (i.e., dysbiosis) can modulate cytotoxic metabolite production, promote neuroinflammation and negatively impact cognition. In this review, we explore critical connections between microbial-derived metabolites (secondary bile acids, trimethylamine-N-oxide (TMAO), tryptophan derivatives and others) and their influence upon cognitive function and neurodegenerative disorders, with a particular interest in their less-explored role as risk factors of cognitive decline.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-022-00548-6

Cites

369 of 369 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Microbial metabolites can directly and indirectly modulate the CNS through immune, neuronal and direct metabolite mediated pathways within the microbiota-gut-brain axis. In the gut lumen, dietary products can be metabolised by microbiota into neuroactive compounds, including neurotransmitters, (e.g., serotonin, dopamine), amino acids (e.g., tryptophan, tryptamine) and other microbial-derived metabolites (e.g., short-chain fatty acids, trimethylamine (TMA)). These compounds subsequently communicate with the central nervous system either directly, travelling through the portal vein, liver and crossing the blood–brain barrier, or indirectly via the production of neurotransmitters by enterochromaffin cells (ECC) or immune pathways (stimulated immune cells produce cytokines that can enter the blood or stimulate the vagus nerve)
Fig. 1 Microbial metabolites can directly and indirectly modulate the CNS through immune, neuronal and direct metabolite mediated pathways within the microbiota-gut-brain axis. In the gut lumen, dietary products can be metabolised by microbiota into neuroactive compounds, including neurotransmitters, (e.g., serotonin, dopamine), amino acids (e.g., tryptophan, tryptamine) and other microbial-derived metabolites (e.g., short-chain fatty acids, trimethylamine (TMA)). These compounds subsequently communicate with the central nervous system either directly, travelling through the portal vein, liver and crossing the blood–brain barrier, or indirectly via the production of neurotransmitters by enterochromaffin cells (ECC) or immune pathways (stimulated immune cells produce cytokines that can enter the blood or stimulate the vagus nerve)CC BY · PubMed Central
Fig. 2 Bile acids, TMAO and tryptophan metabolic pathways and their links to the brain. Primary bile acids are produced from cholesterol breakdown in the liver. They can be conjugated with taurine or glycine residues before travelling to the gut, where they are deconjugated and converted to secondary bile acids via microbial action. Bile acids have been found in the brain of humans and rodents suggesting they can cross the blood–brain barrier via either diffusion (unconjugated) or active transport (conjugated) and influence the central nervous system. TMAO is produced via a two-stage process. TMA is first formed from the microbial conversion of choline in the gut. TMA then travels to the liver, where the FMO1/3 enzyme converts it to TMAO. Recent evidence found TMAO in human brains, indicating it can cross the blood–brain barrier. Tryptophan can be metabolised via three key pathways. Firstly, via gut microbial action, tryptophan can be converted via the indole pathway into numerous indole derivatives, or into the amino acid, tryptamine. Indoles and tryptamine are known to cross the BBB. Secondly, around 3% of dietary tryptophan is metabolised into serotonin and melatonin via numerous enzymes in the serotonin pathway. Notably, serotonin produced in the gut cannot cross the blood–brain barrier. However, the serotonin precursor, 5-hydroxytryptophan, and serotonin derivatives, N-acetylserotonin and melatonin, can cross the blood–brain barrier and influence the central nervous system. Finally, the majority of tryptophan (~ 90–95%) is metabolised via the kynurenine pathway, of which 90% occurs in the liver. This pathway is initiated by the TDO enzyme in the liver and the IDO enzyme in the brain. Only kynurenine, 3-hydroxykynurenine and tryptophan itself can cross the blood–brain barrier. However, once in the brain, tryptophan can be metabolised via both the kynurenine and serotonin pathways to form the pathway’s intermediates
Fig. 2 Bile acids, TMAO and tryptophan metabolic pathways and their links to the brain. Primary bile acids are produced from cholesterol breakdown in the liver. They can be conjugated with taurine or glycine residues before travelling to the gut, where they are deconjugated and converted to secondary bile acids via microbial action. Bile acids have been found in the brain of humans and rodents suggesting they can cross the blood–brain barrier via either diffusion (unconjugated) or active transport (conjugated) and influence the central nervous system. TMAO is produced via a two-stage process. TMA is first formed from the microbial conversion of choline in the gut. TMA then travels to the liver, where the FMO1/3 enzyme converts it to TMAO. Recent evidence found TMAO in human brains, indicating it can cross the blood–brain barrier. Tryptophan can be metabolised via three key pathways. Firstly, via gut microbial action, tryptophan can be converted via the indole pathway into numerous indole derivatives, or into the amino acid, tryptamine. Indoles and tryptamine are known to cross the BBB. Secondly, around 3% of dietary tryptophan is metabolised into serotonin and melatonin via numerous enzymes in the serotonin pathway. Notably, serotonin produced in the gut cannot cross the blood–brain barrier. However, the serotonin precursor, 5-hydroxytryptophan, and serotonin derivatives, N-acetylserotonin and melatonin, can cross the blood–brain barrier and influence the central nervous system. Finally, the majority of tryptophan (~ 90–95%) is metabolised via the kynurenine pathway, of which 90% occurs in the liver. This pathway is initiated by the TDO enzyme in the liver and the IDO enzyme in the brain. Only kynurenine, 3-hydroxykynurenine and tryptophan itself can cross the blood–brain barrier. However, once in the brain, tryptophan can be metabolised via both the kynurenine and serotonin pathways to form the pathway’s intermediatesCC BY · PubMed Central
Fig. 3 Key potential pathways through which microbial-derived metabolites influence cognitive function. An illustration of the main underlying mechanisms linking microbial metabolites and the brain. Dietary-derived precursor molecules can be metabolised by gut microbiota to form bioactive metabolites. These microbial-derived metabolites can influence gut permeability, blood–brain barrier function, neuroinflammation, vagus nerve activation, neurogenesis and excitotoxicity affecting the regulation of the microbiota-gut-brain axis and cognitive function. The green colour highlights a protective and beneficial effect, whereas red indicates a detrimental effect. Acronyms: BBB: blood–brain barrier; DCA: deoxycholic acid; ECC: enterochromaffin cells; FMO: flavin-containing monooxygenase; GABA: γ-aminobutyric acid; IA: indole-3- acrylic acid; IAA: indole-3- acetic acid; IAld: indole-3-aldehyde; ILA: indole-3-lactic acid; I3S: indoxyl-3-sulfate; KYNA; kynurenic acid; LCA: lithocholic acid; NMDAR: N-methyl-D-aspartate receptor; QUIN; quinolinic acid; TMA: trimethylamine; TMAO: trimethylamine N-oxide; TUDCA: tauroursodeoxycholic acid
Fig. 3 Key potential pathways through which microbial-derived metabolites influence cognitive function. An illustration of the main underlying mechanisms linking microbial metabolites and the brain. Dietary-derived precursor molecules can be metabolised by gut microbiota to form bioactive metabolites. These microbial-derived metabolites can influence gut permeability, blood–brain barrier function, neuroinflammation, vagus nerve activation, neurogenesis and excitotoxicity affecting the regulation of the microbiota-gut-brain axis and cognitive function. The green colour highlights a protective and beneficial effect, whereas red indicates a detrimental effect. Acronyms: BBB: blood–brain barrier; DCA: deoxycholic acid; ECC: enterochromaffin cells; FMO: flavin-containing monooxygenase; GABA: γ-aminobutyric acid; IA: indole-3- acrylic acid; IAA: indole-3- acetic acid; IAld: indole-3-aldehyde; ILA: indole-3-lactic acid; I3S: indoxyl-3-sulfate; KYNA; kynurenic acid; LCA: lithocholic acid; NMDAR: N-methyl-D-aspartate receptor; QUIN; quinolinic acid; TMA: trimethylamine; TMAO: trimethylamine N-oxide; TUDCA: tauroursodeoxycholic acidCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 369 references

Research works printed but not linked: 7

  1. Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev Microbiol Nature Publishing Group. 2016;14:20–32. · DOI · Paper page
  2. Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology. 2011;141(599–609):609.e1-3.
  3. Diaz Heijtz R, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A. 2011;108:3047–52. · DOI · Paper page
  4. Hubbard T, Murray I, Bisson W, Lahoti T, Gowda K, Amin S, et al. Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles. Scientific Reports. 2015;5:12689. · DOI · Paper page
  5. Kim L-J, Chalmers TJ, Smith GC, Das A, Poon EWK, Wang J, et al. Nicotinamide mononucleotide (NMN) deamidation by the gut microbiome and evidence for indirect upregulation of the NAD+ metabolome. bioRxiv. Cold Spring Harbor Laboratory; 2020;289561:1–85.
  6. Soda K, Kawakami M. Mediterranean diet and polyamine intake: possible contribution of increased polyamine intake to inhibition of age-associated disease. Nutr Diet Suppl. 2010;3:1.
  7. Bray N. The microbiota–gut–brain axis. Nature Research: Nature Publishing Group; 2019.

Cited by

Sorted by citations

See all 210

Related

Metadata

Authors
Connell, E., Le Gall, G., Pontifex, M. G., Sami, S., Cryan, J. F., Clarke, G., Müller, M., & Vauzour, D.
Affiliations
  • University of East Anglia (GB)
  • University College Cork (IE)
Corresponding author
Vauzour, David
ORCID
Venue
Molecular Neurodegeneration
Publisher
Springer Science and Business Media LLC
Published
2022-06-17
Volume
17
Issue
1
Pages
43-43
ISSN
1750-1326 (ISSN-L)
DOI
10.1186/s13024-022-00548-6
PMC
PMC9204954
OpenAlex
W4283020259
Cited by
208
References
369
Citations by year
2026: 41 · 2025: 60 · 2024: 57 · 2023: 38 · 2022: 12
FWCI
4.39
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UEA Digital Repository (University of East Anglia) (acceptedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
age-related cognitive decline, dementia, microbiota-gut-brain axis, dysbiosis, secondary bile acids, trimethylamine N-oxide, tryptophan derivatives, neuroinflammation, neurodegenerative diseases, gut microbiota, risk factors
MeSH terms
Gastrointestinal Microbiome, Aging, Dementia, Humans, Risk Factors, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review